Literature DB >> 10323681

1,25-(OH)2D3 modulates growth plate chondrocytes via membrane receptor-mediated protein kinase C by a mechanism that involves changes in phospholipid metabolism and the action of arachidonic acid and PGE2.

B D Boyan1, V L Sylvia, D D Dean, H Pedrozo, F Del Toro, I Nemere, G H Posner, Z Schwartz.   

Abstract

1,25-(OH)2D3 (1,25) exerts its effects on growth plate chondrocytes through classical vitamin D (VDR) receptor-dependent mechanisms, resulting in mineralization of the extracellular matrix. Recent studies have shown that membrane-mediated mechanisms are involved as well. 1,25 targets cells in the prehypertrophic and upper hypertrophic zones of the costochondral cartilage growth plate (GC cells), resulting in increased specific activity of alkaline phosphatase (ALP), phospholipase A2 (PLA2), and matrix metalloproteinases (MMPs). At the cellular level, 1,25 action results in rapid changes in arachidonic acid (AA) release and re-incorporation, alterations in membrane fluidity and Ca ion flux, and increased prostaglandin E1 and E2 (PGE2) production. Protein kinase C (PKC) is activated in a phospholipase C (PLC) dependent-mechanism, due in part to the increased production of diacylglycerol (DAG). In addition, AA acts directly on the cell to increase PKC specific activity. AA also provides a substrate for cyclooxygenase (COX), resulting in PGE2 production. 1,25 mediates its effects through COX-1, the constitutive enzyme, but not COX-2, the inducible enzyme. Time course studies using specific inhibitors of COX-1 show that AA stimulates PKC activity and PKC then stimulates PGE2 production. PGE2 acts as a mediator of 1,25 action on the cells, also stimulating PKC activity. The rapid effects of 1,25 on PKC are nongenomic, occurring within 3 min and reaching maximal activation by 9 min. It promotes translocation of PKC to the plasma membrane. When 1,25 is incubated directly with isolated plasma membranes, PKCalpha is stimulated although PKCzeta is also present. In contrast, when isolated matrix vesicles (MVs) are incubated with 1,25, PKCzeta is inhibited and PKCalpha is unaffected. These membrane-mediated effects are due to the presence of a specific membrane vitamin D receptor (mVDR) that is distinct from the classical cytosolic VDR. Studies using 1,25 analogs with reduced binding affinity for the classical VDR, confirm that rapid activation of PKC by 1,25 is not VDR dependent. The membrane-mediated effects of 1,25 are critical to the regulation of events in the extracellular matrix produced by the chondrocytes. MVs are extracellular organelles associated with maturation of the matrix, preparing it for mineralization. MV composition is under genomic control, involving VDR-mechanisms. In the matrix, no new gene expression or protein synthesis can occur, however. Differential distribution of PKC isoforms and their nongenomic regulation by 1,25 is one way for the chondrocyte to control events at sites distant from the cell. GC cells contain 1a-hydroxylase and produce 1,25; this production is regulated by 1,25, 24,25, and dexamethasone. 1,25 stimulates MMPs in the MVs, resulting in increased proteoglycan degradation in mineralization gels, and increased activation of latent transforming growth factor-beta 1 (TGF-beta1).

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10323681     DOI: 10.1016/s0039-128x(98)00099-3

Source DB:  PubMed          Journal:  Steroids        ISSN: 0039-128X            Impact factor:   2.668


  12 in total

Review 1.  Steroid hormone receptors in target cell membranes.

Authors:  R J Pietras; I Nemere; C M Szego
Journal:  Endocrine       Date:  2001-04       Impact factor: 3.633

Review 2.  Vitamin and cofactor biosynthesis pathways in Plasmodium and other apicomplexan parasites.

Authors:  Sylke Müller; Barbara Kappes
Journal:  Trends Parasitol       Date:  2007-02-02

3.  Vitamin D inhibits COX-2 expression and inflammatory response by targeting thioesterase superfamily member 4.

Authors:  Qingsong Wang; Yuhu He; Yujun Shen; Qianqian Zhang; Di Chen; Caojian Zuo; Jing Qin; Hui Wang; Junwen Wang; Ying Yu
Journal:  J Biol Chem       Date:  2014-03-10       Impact factor: 5.157

4.  Stathmin levels in growth plate chondrocytes are modulated by vitamin D3 metabolites and transforming growth factor-beta1 and are associated with proliferation.

Authors:  T W Hummert; Z Schwartz; V L Sylvia; D D Dean; B D Boyan
Journal:  Endocrine       Date:  2001-06       Impact factor: 3.633

5.  1alpha,25(OH)(2) vitamin D(3) induction of ATP secretion in osteoblasts.

Authors:  Payal Biswas; Laura P Zanello
Journal:  J Bone Miner Res       Date:  2009-08       Impact factor: 6.741

6.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

7.  Chaperone properties of pdia3 participate in rapid membrane actions of 1α,25-dihydroxyvitamin d3.

Authors:  Jiaxuan Chen; Kirill S Lobachev; Brian J Grindel; Mary C Farach-Carson; Sharon L Hyzy; Khairat B El-Baradie; Rene Olivares-Navarrete; Maryam Doroudi; Barbara D Boyan; Zvi Schwartz
Journal:  Mol Endocrinol       Date:  2013-05-09

8.  Impaired bone formation in Pdia3 deficient mice.

Authors:  Yun Wang; Alexandr Nizkorodov; Kelsie Riemenschneider; Christopher S D Lee; Rene Olivares-Navarrete; Zvi Schwartz; Barbara D Boyan
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

9.  Matrix vesicles from dental follicle cells improve alveolar bone regeneration via activation of the PLC/PKC/MAPK pathway.

Authors:  Genzheng Yi; Siyuan Zhang; Yue Ma; Xueting Yang; Fangjun Huo; Yan Chen; Bo Yang; Weidong Tian
Journal:  Stem Cell Res Ther       Date:  2022-01-29       Impact factor: 6.832

Review 10.  The Essentiality of Arachidonic Acid in Infant Development.

Authors:  Kevin B Hadley; Alan S Ryan; Stewart Forsyth; Sheila Gautier; Norman Salem
Journal:  Nutrients       Date:  2016-04-12       Impact factor: 5.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.